Drug Trial Radar · NCT00333918
Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery
Last checked: Nov 20, 2026Latest source record: Feb 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
522
Actual
Start
Jun 2006
Primary completion
Mar 2007
Study completion Mar 2007
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jun 6, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to investigate the efficacy and safety of bromfenac ophthalmic solution for treatment of ocular inflammation and pain in subjects who undergo cataract extraction and intraocular lens implantation.
Conditions
- Pain
- Inflammation
Interventions
bromfenac ophthalmic solutionDrug
placebo comparatorDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of ocular inflammation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Irvine, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.